Digital screening plus blood biomarkers to detect early Alzheimer's changes
Official title: Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
Run by Xuanwu Hospital, Beijing · NCT07284264 · Data updated 2026-11-12
This project will test whether a two-step approach—quick digital cognitive screening followed by blood-based biomarker tests—can find early Alzheimer's pathology in community-dwelling adults aged 50 and older who do not have diagnosed cognitive disorders.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 6 sites (Beijing and 5 other locations) |
| Status | Recruiting |
| Started | August 15, 2025 |
| Main results expected | January 1, 2026 |
| Study ends | January 1, 2026 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT07284264 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are community-dwelling adults aged 50 or older in the study regions who have no prior diagnosis of cognitive impairment, can communicate in Chinese, and are willing to complete digital tests and blood sampling.
✕Probably not a fit
People with an established diagnosis of dementia or severe mental illness, those who cannot complete digital cognitive assessments, non-Chinese speakers, or long-term institutionalized patients are unlikely to benefit from this screening approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter observational study uses a stepwise screening strategy beginning with rapid digital pre-screening that combines the SCD-9 questionnaire, a brief digital cognitive assessment, and a predictive risk model to identify people at higher dementia risk. Individuals flagged by the digital screen proceed to blood-based biomarker testing to confirm Alzheimer’s pathology, with multiple novel blood markers compared head-to-head for diagnostic utility. The study recruits community-dwelling adults aged 50 and older without prior diagnoses of mild cognitive impairment or dementia across several medical centers in China. Results aim to identify which combinations of digital measures and blood biomarkers work best for early, scalable detection in real-world community settings.
Why it matters
Potential benefit: If successful, this approach could enable earlier, simpler, and more scalable detection of Alzheimer's pathology using routine digital screening combined with blood tests, allowing earlier support or preventive strategies.
How similar studies have gone: Previous research has shown promising results for plasma Alzheimer's biomarkers and digital cognitive tests, but direct head-to-head comparisons of multiple novel blood markers in large community screening programs remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. adults aged 50 and above; 2. living in community for at least one year and having established medical records; 3. denying a history of cognitive disorders (mild cognitive impairment, dementia, Alzheimer's disease, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.); 4. agreeing to participate in the study; 5. individual or their relatives can communicate normally in Chinese. 6. high-risk groups for dementia(including:1. Complaints of cognitive decline and/or statements by the informant;2. History of AD in first-degree relatives;3. Known ApoE e4 carrier.) Exclusion Criteria: 1. Self-reporting or confirmation through inquiry indicates the presence of severe mental disorders, such as bipolar disorder or schizophrenia, etc. 2. Having a disease that makes it impossible to complete the cognitive assessment.
Where it's running
-
Xuanwu Hospital, Capital Medical University
Beijing, China Recruiting -
Hainan Medical University
Hainan, China Recruiting -
General Hospital of Ningxia Medical University
Ningxiang, China Recruiting -
The First Hospital of China Medical Unversity
Shenyang, China Recruiting -
Shenzhen Center For Chronic Disease Control
Shenzhen, China Recruiting -
Yichun People'S Hospital
Yichun, China Recruiting
Study contacts
- Principal investigator: Yi Tang, M.D., Ph.D — Xuanwu Hospital, Beijing
- Study coordinator: Yi Tang, M.D., Ph.D
- Email: tangyixw@vip.163.com
- Phone: 00861083199456
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers
This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Doll Therapy for Apathy and Daily Living in Older Adults with Dementia
This study tests whether doll therapy helps reduce apathy and improves starting daily activities in older adults with dementia.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.